Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Monogram Orthopaedics  / Equity Bottom-Up

Monogram Orthopaedics Inc. is a medical technology company. The Company produces and markets robotic surgical equipment and related software, orthopaedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Monogram Orthopaedics serves customers in the United States.

<ul><li>Monogram Technologies (NASDAQ: MGRM) is a medical device company developing a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging.</li><li> On 5/17/25, the company received clearance from the FDA on its 510(k) submission for its mB s TKA System.</li><li>The first live in patient surgery OUS is expected in early 2025.</li></ul>

Monogram Technologies (NASDAQ: MGRM) is a medical device company developing a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. On 5/17/25, the company received clearance from the FDA on its 510(k) submission for its mB s TKA System.The first live in patient surgery OUS is expected in early 2025.

MGRM:  Monogram receives clearance from the FDA on its 510(k) submission for its mB s TKA System. The company can now move forward with upgrades to the system and begin the commercialization process.

Adaptimmune Therapeutics  / Equity Bottom-Up

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company develops novel cancer immunotherapy products based on T-cell receptor platform that helps to identify cancer targets. Adaptimmune Therapeutics serves customers worldwide.

<ul><li>Zacks Small-Cap Research Note for Adaptimmune Therapeutics plc (ADAP)</li></ul>

Zacks Small-Cap Research Note for Adaptimmune Therapeutics plc (ADAP)

Longeveron Inc. operates as a clinical stage biotechnology company. The Company focuses on developing cellular therapies for specific aging-related and life-threatening conditions. Longeveron serves customers worldwide.

<ul><li>Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease.</li><li> The company announced that it had a positive meeting with the FDA regarding the testing of Lomecel-B for the treatment of Alzheimer's.</li><li>The end result is the testing and approval process could be accelerated.</li></ul>

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease. The company announced that it had a positive meeting with the FDA regarding the testing of Lomecel-B for the treatment of Alzheimer's.The end result is the testing and approval process could be accelerated.

LGVN: Alzheimer's Treatment Gets Positive News from FDA

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

WuXi AppTec Co., Ltd. manufactures medical products. The Company produces biological agents, antibodies, biological diagnostic reagents, and other products. WuXi AppTec also provides biological analysis, technical study, and other services.

<ul>
<li>WuXi AppTec’s 2024 results are in line with guidance. TIDES business was the key driver of WuXi Chemistry. However, the downturn of “R” business cast a shadow on performance recovery.</li>
<li>2025 is a crucial year for WuXi AppTec and the entire CXO industry, as it needs to verify whether about RMB40 billion revenue and 6,000 customers represent the ceiling/growth bottleneck?</li>
<li>The disposal of WuXi XDC shares help boost WuXi AppTec’s share price. However, due to the geopolitical conflicts/recession risks, the long-term growth prospects of WuXi AppTec are still uncertain.</li>
</ul>


WuXi AppTec’s 2024 results are in line with guidance. TIDES business was the key driver of WuXi Chemistry. However, the downturn of “R” business cast a shadow on performance recovery.
2025 is a crucial year for WuXi AppTec and the entire CXO industry, as it needs to verify whether about RMB40 billion revenue and 6,000 customers represent the ceiling/growth bottleneck?
The disposal of WuXi XDC shares help boost WuXi AppTec’s share price. However, due to the geopolitical conflicts/recession risks, the long-term growth prospects of WuXi AppTec are still uncertain.


WuXi AppTec (2359.HK/603259.CH) - The Concerns Behind the 2024 Performance Rebound and 2025 Outlook

Global Healthcare Analyst

Tina Banerjee

Lotus Pharmaceutical Co., Ltd. manufactures and distributes oral medicine, ointment and injection medicine.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/lotus-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:20568:1" rel="noopener">Lotus Pharmaceutical (1795 TT)</a> achieved 10% revenue growth to NT$19B in 2024, while net profit increased 23% to NT$5B. Growth was mainly driven by the strong performance of export business.</li>
<li>For the first two months of 2025, the company reported revenue of NT$3B, representing 3% YoY growth. Particularly, January sales marked 9% YoY and a significant 48% MoM growth.</li>
<li>New launches and geography expansion of existing drugs will drive near-term growth. Lotus expects to launch 11 products in 2025. Valuation remains attractive and long-term growth story is still intact.</li>
</ul>



Lotus Pharmaceutical (1795 TT) achieved 10% revenue growth to NT$19B in 2024, while net profit increased 23% to NT$5B. Growth was mainly driven by the strong performance of export business.
For the first two months of 2025, the company reported revenue of NT$3B, representing 3% YoY growth. Particularly, January sales marked 9% YoY and a significant 48% MoM growth.
New launches and geography expansion of existing drugs will drive near-term growth. Lotus expects to launch 11 products in 2025. Valuation remains attractive and long-term growth story is still intact.


Lotus Pharmaceutical (1795 TT): Six Consecutive Years of Double-Digit Growth; Momentum to Continue

Health Care
Several billion reasons

MGRM: Monogram receives clearance from the FDA on its 510(k) submission for its mB s TKA System. The company can now move forward with upgrades to the system and begin the commercialization process.

Monogram Technologies (NASDAQ: MGRM) is a medical device company developing a product solution architecture to enable patient-optimized orthopedic...

Zacks Small Cap Research

ADAP: 4Q24 Business Update

Zacks Small-Cap Research Note for Adaptimmune Therapeutics plc (ADAP)

Zacks Small Cap Research

LGVN: Alzheimer's Treatment Gets Positive News from FDA

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...

Zacks Small Cap Research

WuXi AppTec (2359.HK/603259.CH) - The Concerns Behind the 2024 Performance Rebound and 2025 Outlook

WuXi AppTec 2024 results showed recovery, but challenges in "R" business raise concerns for 2025 growth.Geopolitical/recession risk cloud long...

Xinyao (Criss) Wang

Lotus Pharmaceutical (1795 TT): Six Consecutive Years of Double-Digit Growth; Momentum to Continue

Lotus Pharmaceutical sees record high revenue, gross profit margin, and profit in 2024, driven by export business. The company should witness...

Tina Banerjee

MGRM: Monogram receives clearance from the FDA on its 510(k) submission for its mB s TKA System. The company can now move forward with upgrades to the system and begin the commercialization process.

Monogram Technologies (NASDAQ: MGRM) is a medical device company developing a product solution architecture to enable patient-optimized orthopedic...

Zacks Small Cap Research

ADAP: 4Q24 Business Update

Zacks Small-Cap Research Note for Adaptimmune Therapeutics plc (ADAP)

Zacks Small Cap Research

LGVN: Alzheimer's Treatment Gets Positive News from FDA

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...

Zacks Small Cap Research

WuXi AppTec (2359.HK/603259.CH) - The Concerns Behind the 2024 Performance Rebound and 2025 Outlook

​WuXi AppTec 2024 results showed recovery, but challenges in "R" business raise concerns for 2025 growth.Geopolitical/recession risk cloud long...

Xinyao (Criss) Wang

Lotus Pharmaceutical (1795 TT): Six Consecutive Years of Double-Digit Growth; Momentum to Continue

​Lotus Pharmaceutical sees record high revenue, gross profit margin, and profit in 2024, driven by export business. The company should witness...

Tina Banerjee

WuXi AppTec 2024 results showed recovery, but challenges in "R" business raise concerns for 2025 growth.Geopolitical/recession risk cloud long...

Lotus Pharmaceutical sees record high revenue, gross profit margin, and profit in 2024, driven by export business. The company should witness...